




# PHARMACEUTICAL 2019

Revance Therapeutics Inc.  
Rank 204 of 363

REVANCE®





# PHARMACEUTICAL 2019

Revance Therapeutics Inc.  
Rank 204 of 363

REVANCE®

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 68% points. The greatest weakness of Revance Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 70%, being 33% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	207,922
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,970
Liabilities, Non-Current	42,684
Other Assets	3,977
Other Compr. Net Income	-8.0
Other Expenses	3,044
Other Liabilities	6,072
Other Net Income	3,110
Other Revenues	3,729
Property and Equipment	14,449
Research and Development	92,500
Selling, General and Administrative Expense	53,863

Output Variable	Value in 1000 USD
Assets	226,348
Liabilities	80,726
Expenses	149,407
Revenues	3,729
Stockholders Equity	145,622
Net Income	-142,568
Comprehensive Net Income	-142,572
Economic Capital Ratio	70%